Hero Background Image
Market Commentary

Baron Health Care Fund: Latest Insights and Commentary

Top Contributors/Detractors to Performance

As of 09/30/2026

CONTRIBUTORS

  • Thermo Fisher Scientific Inc. is a global life sciences company offering analytical instruments, laboratory products, biopharmaceutical services, and specialty diagnostics. Shares rose on better-than-expected second-quarter results. Organic growth of 5% exceeded consensus by 200 basis points, and management raised full-year organic growth guidance to the top of its prior range, driven by improving pharmaceutical and biotechnology spending. Bioproduction remained a standout franchise, while the divestiture of the lower-quality microbiology business funded additional share repurchases. We retain conviction that the life sciences tools industry can return to growth approximately two percentage points above GDP and believe Thermo Fisher’s scale, disciplined capital allocation, and broad-based margin expansion position the company to lead the recovery.
  • Mettler-Toledo International Inc. is a leading provider of precision instruments and services used in research and development, quality control, and manufacturing processes across the life sciences, food, and chemicals industries. The stock contributed to performance following strong second-quarter results and a raised full-year outlook. Local-currency sales grew 6%, exceeding prior guidance of 3%, supported by better-than-expected growth in China and strength across other emerging markets. Earnings per share (EPS) of $11.46 also exceeded sell-side estimates of $10.80. In addition, positive commentary on business trends from life sciences tools peers, including Thermo Fisher Scientific and Agilent, contributed to Mettler-Toledo’s share price appreciation. We think the company is well positioned to benefit from several positive trends, including life sciences investment in China and new U.S. plant construction by biopharmaceutical companies. Over the long term, we believe Mettler-Toledo can generate mid-teens or better annual EPS growth.
  • Global pharmaceutical company Teva Pharmaceutical Industries Limited contributed to performance, outpacing the broader pharmaceutical sector. Second-quarter results showed strength in Teva’s branded innovative portfolio, with Austedo, Ajovy, and Uzedy collectively growing 43% year-over-year to more than $1 billion in quarterly revenue for the first time. Management raised guidance for all three brands, targeting combined 2026 revenue of approximately $3.7 billion, or roughly 17% year-over-year growth at the midpoint. Sentiment also benefited from Teva’s plan to replace its American Depositary Share program with a direct listing of ordinary shares on the New York Stock Exchange, a move designed to broaden its investor base and reduce financing costs. Pipeline progress added another catalyst, with investigational celiac disease drug TEV ’408 meeting its primary endpoint and the U.S. Food and Drug Administration accepting a drug application for a pediatric Tourette syndrome therapy. These developments underscore Teva’s transformation from a generics-heavy business into a diversified innovative biopharmaceutical company with a deepening pipeline and improving financial profile.

 

DETRACTORS

  • UnitedHealth Group Incorporated, a diversified health care and benefits company operating through UnitedHealthcare and Optum, detracted from performance. While Medicare Advantage cost trends came in better than expected following an especially challenging 2025, elevated commercial utilization raised investor concerns, though we believe annual repricing can close the gap. Management also flagged pressure from No Surprises Act arbitration and increasingly aggressive provider billing, pushing the expected margin recovery beyond the prior 2027 target. Election-related policy uncertainty added another overhang across managed care, while the then-pending 2027 Medicare Advantage Star Ratings further pressured shares. We believed management had planned for a range of outcomes and was comfortable with its Star positioning, with the ability to redirect growth toward higher-rated plans if needed, as it had done in the past. We retain long-term conviction and view UnitedHealth’s 13% to 16% earnings-per-share growth target as intact.
  • Biopharmaceutical company Xenon Pharmaceuticals Inc. detracted from performance after voluntarily pausing enrollment of new patients in its Phase 3 depression studies following the emergence of neuropsychiatric adverse events, including confusion, somnolence, ataxia, and rare cases of psychosis. The announcement was particularly disappointing because it coincided with what otherwise should have been a positive catalyst: the submission of a New Drug Application to the U.S. Food and Drug Administration for azetukalner as a treatment for focal seizures in epilepsy, supported by strong pivotal trial data. Investors questioned whether the safety signals observed at higher doses in the depression studies could complicate the regulatory review of azetukalner for epilepsy or result in label restrictions, a Risk Evaluation and Mitigation Strategy, or heightened post-marketing requirements that could limit the drug’s commercial potential. We chose to exit our position.
  • Pharmaceutical company Eli Lilly and Company detracted from performance as pricing pressure and competitive concerns weighed on sentiment. Shares declined following the company’s second-quarter earnings release as realized U.S. prices for its GLP-1 drugs declined approximately 9% excluding rebate adjustments, fueling concerns that the incretin market is entering a price-war phase. Meanwhile, early prescription growth for Lilly’s oral GLP-1 Foundayo also fell short of investor expectations. Foundayo was approved and launched in April, but Lilly did not begin marketing the drug until payer coverage was in place. Despite these concerns, Lilly continues to deliver strong underlying financial results, including 48% second-quarter revenue growth. Prescription trends for Foundayo have also started to improve. Our focus remains on the long-term potential of Lilly’s broader GLP-1 franchise and business rather than solely on Foundayo’s early launch. We continue to believe Lilly has one of the strongest next-generation metabolic pipelines in the industry, addressing a market we believe can exceed $150 billion.

Quarterly Attribution Analysis (Institutional Shares)

As of 09/30/2026

When reviewing performance attribution on our portfolio, please be aware that we construct the portfolio from the bottom up, one stock at a time. Each stock is included in the portfolio if it meets our rigorous investment criteria. To help manage risk, we are aware of our sector and security weights, but we do not include a holding to achieve a target sector allocation or to approximate an index. Our exposure to any given sector is purely a result of our stock selection process.

Baron Health Care Fund (the Fund) increased 4.02% (Institutional Shares) in the third quarter, trailing the Russell 3000 Health Care Index (the Index), which rose 6.19%. The Fund underperformed by 217 basis points as disappointing stock selection in a few sub-industries overshadowed favorable impact from being meaningfully overexposed to life sciences tools & services stocks.

Biotechnology was responsible for the majority of the shortfall, detracting 235 basis points from relative results, as the sub-industry's solid headline return in the Index masked wide dispersion beneath the surface. The single largest stock-specific headwind came from not owning Moderna, Inc., whose shares nearly tripled after the company announced that its personalized mRNA cancer vaccine in combination with Merck & Co., Inc.’s KEYTRUDA as adjuvant therapy demonstrated statistically significant and clinically meaningful improvements in recurrence-free survival and distant metastasis-free survival compared to KEYTRUDA alone for patients with completely resected stage IIB-IV melanoma who had not undergone prior treatment with systemic therapy. We thought there was a high probability that this trial would succeed, but we also thought success in adjuvant melanoma would not necessarily translate into success in other cancers because melanoma is uniquely responsive to immunotherapy. We look forward to seeing data from Moderna/Merck trials with intismeran in other cancers.

Adverse stock selection in biotechnology was further compounded by limited exposure to larger-cap companies Amgen Inc., Gilead Sciences, Inc., and Regeneron Pharmaceuticals, Inc., all of which rallied in the quarter.  Most of the remaining weakness was attributable to losses from Xenon Pharmaceuticals Inc., which is developing azetukalner, a Kv7 Potassium channel opener, for epilepsy and depression, and Cytokinetics, Incorporated, which is commercializing a MYQORZO, a cardiac myosin inhibitor for hypertrophic cardiomyopathy.  Xenon detracted from performance after voluntarily pausing enrollment of new patients in its Phase 3 depression studies following the emergence of neuropsychiatric adverse events, including confusion, somnolence, ataxia, and rare cases of psychosis. The announcement was particularly disappointing because it coincided with what otherwise should have been a positive catalyst: the submission of a New Drug Application to the U.S. Food and Drug Administration for azetukalner as a treatment for focal seizures in epilepsy, supported by strong pivotal trial data. Investors questioned whether the safety signals observed at higher doses in the depression studies could complicate the regulatory review of azetukalner for epilepsy or result in label restrictions, a Risk Evaluation and Mitigation Strategy, or heightened post-marketing requirements that could limit the drug’s commercial potential. We chose to exit our position.

Shares of Cytokinetics struggled in the third quarter after its second-quarter update showed MYQORZO (aficamten) generating just $25 million in net product revenue across roughly 1,500 patients, below the market’s more aggressive launch expectations. Sentiment weakened further in late August when full ACACIA-HCM results, published in the New England Journal of Medicine, showed a higher rate of serious adverse events on aficamten than placebo, including two cases of heart failure with reduced ejection fraction—raising questions about the monitoring the U.S. Food and Drug Administration (FDA) may require in the broader non-obstructive HCM population. As a result, we reduced our position.

Pharmaceuticals was another material detractor, subtracting 96 basis points from relative results. The Fund's unique position in AstraZeneca PLC was the primary culprit, as shares fell 17.5% in the period after the Phase 3 SERENA-4 trial of camizestrant (marketed as Etcamah) plus palbociclib failed to meet its primary endpoint of progression-free survival in the broad, unselected first-line advanced breast cancer population, narrowing the drug's addressable opportunity mainly to patients who develop an emergent ESR1 mutation. Given the reduced peak sales potential for one of the company's key growth pipeline assets, we exited our position. Innovative animal health solutions provider Elanco Animal Health Incorporated also detracted, as investors became concerned about a price war with Zoetis which has been losing market share to Elanco. We remain shareholders, as we believe concerns about a price war are overblown, and we remain encouraged by the company's market share gains, margin improvement, and continued deleveraging. Lack of exposure to Index heavyweight Pfizer Inc., which rose 20.5%, along with weakness in Definium Therapeutics, Inc. and Veradermics, Incorporated, further pressured relative results.

Somewhat offsetting the above was the Fund’s large overweight to life sciences tools & services, which contributed 190 basis points. The sub-industry staged a broad-based recovery after several difficult years marked by post-pandemic destocking, weak demand from China, and cautious biopharmaceutical R&D budgets. Biopharmaceutical funding levels rebounded to their highest quarterly total since late 2021, underlying clinical pipeline activity continued to expand, and a long-awaited bioprocessing and lab-instrument replacement cycle gained traction, prompting several bellwethers to beat expectations and raise full-year guidance during the quarter. 

Health care services and managed health care rounded out the quarter's positive contributors. RadNet, Inc., the largest owner and operator of outpatient diagnostic imaging centers, drove strength in health care services, with shares rising 13.0% as the company’s core imaging center business continued to deliver strong results. Advanced imaging volumes (MRI, CT, and PET/CT) grew 21.2% in aggregate and 9.6% on a same center basis, lifting the advanced imaging mix by 238 basis points to 29.9% of the business. We believe this trend has substantial runway driven by a combination of new clinical indications (particularly prostate and Alzheimer's PET/CT studies), a secular mix shift toward higher-acuity modalities, and capacity expansion through new center openings and AI-enabled technology such as TechLive. 

Managed health care stocks gave back a portion of their robust gains from the prior quarter, with the sub-industry falling nearly 9% in the Index, amid lingering uncertainty around Medicare Advantage Star Ratings and concerns about the upcoming election. Lower relative exposure to UnitedHealth Group Incorporated and to the broader sub-industry was a modest tailwind to relative performance.